PDS Biotechnology (NASDAQ:PDSB) Price Target Lowered to $7.00 at B. Riley

PDS Biotechnology (NASDAQ:PDSB) had its price target trimmed by B. Riley from $9.00 to $7.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other analysts have also recently commented on the company. StockNews.com cut PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. Alliance Global Partners raised PDS Biotechnology to a “strong-buy” rating in a research note on Wednesday, August 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price target on shares of PDS Biotechnology in a research note on Friday, November 15th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Stock Performance

Shares of PDSB stock opened at $2.17 on Monday. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. The stock has a market cap of $81.18 million, a PE ratio of -1.87 and a beta of 1.93. The stock has a 50-day moving average of $3.10 and a 200-day moving average of $3.19. PDS Biotechnology has a one year low of $1.53 and a one year high of $6.68.

Institutional Trading of PDS Biotechnology

A number of large investors have recently bought and sold shares of PDSB. Tempus Wealth Planning LLC bought a new stake in PDS Biotechnology during the 2nd quarter worth approximately $55,000. Ground Swell Capital LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $115,000. Squarepoint Ops LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $120,000. Finally, Cubist Systematic Strategies LLC acquired a new position in PDS Biotechnology during the 2nd quarter worth approximately $146,000. 26.84% of the stock is owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.